TEE
CDTX

Tibra Equities Europe’s Cidara Therapeutics CDTX Stock Holding History

Tibra Equities Europe’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,745
Closed -$353K – 70
2021
Q2 		$353K Buy
+8,745
New +$370K 0.11% 52

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Tibra Equities Europe's CDTX Position: Q3 2021 in Review

Tibra Equities Europe sold out of Cidara Therapeutics (CDTX) in Q3 2021, closing a stake of 8,745 shares — an estimated $353K sold.

Tibra Equities Europe first reported a position in CDTX in Q2 2021 and held it in 1 quarter. The position peaked at $353K in Q2 2021. 50 funds tracked by Wall St. Rank hold CDTX as of Q3 2021.

  • Tibra Equities Europe reported no remaining Cidara Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 8,745 Cidara Therapeutics shares in Q3 2021, an estimated $353K.
  • Tibra Equities Europe first reported a position in Cidara Therapeutics in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Cidara Therapeutics position peaked at $353K in Q2 2021.
  • 50 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.